DK2699587T3 - Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil - Google Patents
Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil Download PDFInfo
- Publication number
- DK2699587T3 DK2699587T3 DK12720966.6T DK12720966T DK2699587T3 DK 2699587 T3 DK2699587 T3 DK 2699587T3 DK 12720966 T DK12720966 T DK 12720966T DK 2699587 T3 DK2699587 T3 DK 2699587T3
- Authority
- DK
- Denmark
- Prior art keywords
- mutant
- methods
- clostridium difficile
- difficile toxin
- compositions related
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478474P | 2011-04-22 | 2011-04-22 | |
US201161478899P | 2011-04-25 | 2011-04-25 | |
PCT/IB2012/051999 WO2012143902A1 (en) | 2011-04-22 | 2012-04-20 | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2699587T3 true DK2699587T3 (da) | 2019-08-05 |
Family
ID=46085103
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19167276.5T DK3549949T3 (da) | 2011-04-22 | 2012-04-20 | Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil |
DK12720966.6T DK2699587T3 (da) | 2011-04-22 | 2012-04-20 | Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19167276.5T DK3549949T3 (da) | 2011-04-22 | 2012-04-20 | Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil |
Country Status (29)
Country | Link |
---|---|
US (13) | US8481692B2 (da) |
EP (4) | EP2699587B1 (da) |
JP (8) | JP5917682B2 (da) |
KR (1) | KR101667837B1 (da) |
CN (3) | CN111647059B (da) |
AR (1) | AR086199A1 (da) |
AU (6) | AU2012245904B2 (da) |
BR (2) | BR112013027229B1 (da) |
CA (1) | CA2832712C (da) |
CO (1) | CO6801643A2 (da) |
DK (2) | DK3549949T3 (da) |
ES (3) | ES2742823T3 (da) |
FI (1) | FI3549949T3 (da) |
HR (2) | HRP20231631T1 (da) |
HU (2) | HUE065594T2 (da) |
IL (8) | IL270779B1 (da) |
MX (1) | MX347521B (da) |
MY (2) | MY182429A (da) |
NZ (1) | NZ616035A (da) |
PE (2) | PE20141029A1 (da) |
PL (3) | PL3549949T3 (da) |
PT (2) | PT3549949T (da) |
RU (2) | RU2754446C2 (da) |
SA (3) | SA115360698B1 (da) |
SG (3) | SG194132A1 (da) |
SI (3) | SI3505531T1 (da) |
TW (6) | TWI686402B (da) |
WO (1) | WO2012143902A1 (da) |
ZA (1) | ZA201307818B (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2507553T3 (es) * | 2006-08-02 | 2014-10-15 | Johannes Gutenberg-Universität Mainz | Fármaco contra intoxicaciones por LCT |
SI2759306T1 (sl) * | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
HRP20231631T1 (hr) | 2011-04-22 | 2024-03-15 | Wyeth Llc | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
PL2888283T3 (pl) | 2012-08-24 | 2019-03-29 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
PL2916866T3 (pl) * | 2012-11-06 | 2018-10-31 | Bayer Pharma Aktiengesellschaft | Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite) |
US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
CA2910200A1 (en) * | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
US9730994B2 (en) | 2013-06-14 | 2017-08-15 | Sanofi Pasteur, Inc. | Compositions and methods for immunizing against C. difficile |
US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
US10500263B2 (en) * | 2014-07-25 | 2019-12-10 | Biosynth S.R.L. | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
EP3256855B1 (en) * | 2015-02-13 | 2020-10-07 | Quanterix Corporation | Immunoassays for diffrential detection of clostridium difficile |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
US20190211377A1 (en) * | 2016-12-22 | 2019-07-11 | Roche Molecular Systems, Inc. | Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile |
CN111629750B (zh) | 2017-09-28 | 2024-06-11 | 辉瑞公司 | 用于引发针对艰难梭菌的免疫应答的组合物和方法 |
WO2020201985A1 (en) | 2019-04-01 | 2020-10-08 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
WO2020231859A1 (en) * | 2019-05-10 | 2020-11-19 | The Board Of Regents Of The University Of Oklahoma | Clostridioides difficile tcdb variants, vaccines and methods of use |
WO2020231930A1 (en) * | 2019-05-11 | 2020-11-19 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
KR102376876B1 (ko) | 2020-04-09 | 2022-03-21 | 대진대학교 산학협력단 | 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도 |
CA3177003A1 (en) * | 2020-05-06 | 2021-11-11 | Vern L. Schramm | Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb |
WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
CN111755068B (zh) * | 2020-06-19 | 2021-02-19 | 深圳吉因加医学检验实验室 | 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置 |
WO2023175454A1 (en) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Methods for producing an adjuvant |
WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
WO2024127215A2 (en) | 2022-12-13 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58216123A (ja) | 1982-06-10 | 1983-12-15 | Kazue Ueno | 抗血清 |
US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
US4713240A (en) | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5599539A (en) | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5578308A (en) | 1990-02-12 | 1996-11-26 | Capiau; Carine | Glutaraldehyde and formalin detoxified bordetella toxin vaccine |
US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
JPH06509866A (ja) | 1991-04-22 | 1994-11-02 | マサチューセッツ ヘルス リサーチ インスティチュート,インコーポレーテッド | 呼吸系ウイルスに対する有効な抗体力価用の血漿試料をスクリーニングする方法 |
US6221363B1 (en) | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
ATE240117T1 (de) | 1993-03-29 | 2003-05-15 | Pfizer | Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt |
NZ291659A (en) | 1994-09-06 | 2001-04-27 | Galagen Inc | Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile |
CZ296806B6 (cs) | 1994-10-24 | 2006-06-14 | Allergan, Inc. | Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu |
US6743430B1 (en) | 1995-03-29 | 2004-06-01 | Richard E. Parizek | Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose |
US5610023A (en) | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
WO1997002835A1 (en) | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Intranasal vaccination against gastrointestinal disease |
US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
JPH11509200A (ja) | 1995-07-07 | 1999-08-17 | オラバックス インク. | 粘膜アジュバントとしてのクロストリジウム・ディフィシール(Clostridium Difficile)トキシン |
EP0952773B1 (en) * | 1995-09-15 | 2005-11-23 | Dale N. Gerding | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
EP0912955A2 (en) | 1996-07-12 | 1999-05-06 | Edwin C. Iliff | Computerized medical diagnostic system utilizing list-based processing |
CZ94899A3 (cs) | 1996-09-30 | 1999-09-15 | Embrex, Inc. | Vakcinační přípravek použitelný při produkci aktivní imunity, použití a způsob jeho přípravy |
US20100267012A1 (en) | 1997-11-04 | 2010-10-21 | Bergeron Michel G | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US20050106157A1 (en) | 1997-05-27 | 2005-05-19 | Deckers Harm M. | Immunogenic formulations comprising oil bodies |
EP1000155A1 (en) | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
WO1999020304A1 (en) | 1997-10-20 | 1999-04-29 | Oravax, Inc. | Passive immunization against clostridium difficile disease |
EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン |
US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
EP1165796A2 (en) * | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
GB0008682D0 (en) | 2000-04-07 | 2000-05-31 | Microbiological Res Authority | Transformation of clostridium difficile |
WO2001082788A2 (en) * | 2000-05-04 | 2001-11-08 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
DK1397380T3 (da) * | 2001-06-20 | 2007-05-07 | Univ Ramot | Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
EP1514928B1 (en) | 2002-06-05 | 2013-07-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing antibodies using baculoviruses |
US7226597B2 (en) * | 2002-06-17 | 2007-06-05 | The Board Of Regents Of The University Of Oklahoma | Mutants of Clostridium difficile toxin B and methods of use |
US20040235139A1 (en) | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
EP1601689B1 (en) * | 2003-03-13 | 2007-11-28 | GlaxoSmithKline Biologicals S.A. | Purification process for bacterial cytolysin |
US20050020506A1 (en) | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
WO2005069913A2 (en) | 2004-01-16 | 2005-08-04 | Dow Global Technologies Inc. | Expression of mammalian proteins in pseudomonas fluorescens |
NZ530709A (en) | 2004-01-21 | 2006-07-28 | Agres Ltd | Improved IGA production method |
KR20120083534A (ko) | 2004-02-06 | 2012-07-25 | 메다렉스, 인코포레이티드 | 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도 |
GB0421083D0 (en) * | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
EP1833510A4 (en) * | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
WO2006130925A1 (en) | 2005-06-10 | 2006-12-14 | Monash University | Genetic manipulation of clostridium difficile |
GB0512751D0 (en) | 2005-06-22 | 2005-07-27 | Glaxo Group Ltd | New adjuvant |
WO2007090126A2 (en) * | 2006-01-30 | 2007-08-09 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
CN101460192A (zh) * | 2006-03-30 | 2009-06-17 | 恩布里克斯公司 | 家禽疫苗接种的方法和组合物 |
WO2007146139A2 (en) * | 2006-06-08 | 2007-12-21 | Cornell Research Foundation, Inc. | Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b |
GB0612301D0 (en) | 2006-06-21 | 2006-08-02 | Morvus Technology Ltd | DNA molecules and methods |
US20080206819A1 (en) | 2006-08-21 | 2008-08-28 | Mary Tsao | Intensified Perfusion Production Method |
US7775167B2 (en) | 2006-08-22 | 2010-08-17 | Monsanto Technology Llc | Custom planter and method of custom planting |
EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US9023352B2 (en) * | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
EP2116997A4 (en) * | 2007-03-02 | 2011-11-23 | Panasonic Corp | AUDIO DECODING DEVICE AND AUDIO DECODING METHOD |
EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
US9096638B2 (en) | 2007-09-06 | 2015-08-04 | Geneohm Sciences Canada, Inc. | Detection of toxigenic strains of Clostridium difficile |
ES2657485T3 (es) * | 2007-09-14 | 2018-03-05 | Sanofi Pasteur Biologics, Llc | Composiciones farmacéuticas que contienen toxoides A y B de Clostridium difficile |
WO2009132082A2 (en) * | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
US8206940B2 (en) | 2008-05-15 | 2012-06-26 | Tufts University | Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression |
JP5712126B2 (ja) | 2008-06-25 | 2015-05-07 | ノバルティス アーゲー | 遅延型追加刺激免疫処置に対する迅速な応答 |
EP2146490A1 (en) | 2008-07-18 | 2010-01-20 | Alcatel, Lucent | User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems |
WO2010017383A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
US9115347B2 (en) | 2008-09-24 | 2015-08-25 | Sanofi Pasteur Biologies, LLC | Methods and compositions for increasing toxin production |
US8444996B2 (en) | 2008-10-01 | 2013-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia |
WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
UA105508C2 (uk) | 2008-12-03 | 2014-05-26 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Спосіб одержання вакцини проти clostridium difficile |
SI2759306T1 (sl) | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
GB0901001D0 (en) * | 2009-01-22 | 2009-03-04 | Univ Nottingham | Methods |
WO2010094970A1 (en) * | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
JP2013503198A (ja) | 2009-08-27 | 2013-01-31 | シナプティック リサーチ,リミテッド ライアビリティ カンパニー | 人工多能性幹(iPS)細胞または組織特異的細胞を誘導するための新規タンパク質送達系 |
WO2011060431A2 (en) * | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
AU2010325992A1 (en) * | 2009-12-02 | 2012-05-31 | Tufts University | Atoxic recombinant holotoxins of Clostridium difficile as immunogens |
GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
CN101870978A (zh) * | 2010-03-23 | 2010-10-27 | 王世霞 | 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗 |
JP5839411B2 (ja) | 2010-03-30 | 2016-01-06 | フェニックス インク. | 組み換え型毒素タンパク質の高レベルの発現 |
US8765399B2 (en) | 2010-05-18 | 2014-07-01 | Montefiore Medical Center | Cultures and protocols for diagnosis of toxigenic Clostridium difficile |
KR101907434B1 (ko) * | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
WO2012078313A2 (en) * | 2010-11-12 | 2012-06-14 | Reflexion Pharmaceuticals, Inc. | Gb1 peptidic libraries and compounds, and methods of screening the same |
HRP20231631T1 (hr) * | 2011-04-22 | 2024-03-15 | Wyeth Llc | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
ES2615737T3 (es) | 2011-05-27 | 2017-06-08 | Glaxosmithkline Biologicals S.A. | Composición inmunogénica |
US9770500B2 (en) * | 2011-05-31 | 2017-09-26 | The Board Of Regents Of The University Of Texas System | S-nitrosylation of glucosylating toxins and uses therefor |
SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
JP2015529677A (ja) | 2012-09-19 | 2015-10-08 | ノバルティス アーゲー | ワクチンとしてのClostridiumdifficileポリペプチド |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
EP2925362A4 (en) | 2012-11-28 | 2016-07-20 | Cnj Holdings Inc | ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE |
LT2928489T (lt) | 2012-12-05 | 2019-04-10 | Glaxosmithkline Biologicals S.A. | Imunogeninė kompozicija |
GB201223342D0 (en) | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
AU2014228956A1 (en) | 2013-03-15 | 2015-10-08 | Sanofi Pasteur, Inc. | Toxoid, compositions and related methods |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
EP2981611A4 (en) | 2013-04-02 | 2016-11-16 | Stc Unm | ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH |
US9730994B2 (en) | 2013-06-14 | 2017-08-15 | Sanofi Pasteur, Inc. | Compositions and methods for immunizing against C. difficile |
WO2015061529A1 (en) | 2013-10-23 | 2015-04-30 | The Rockefeller University | Compositions and methods for prophylaxis and therapy of clostridium difficile infection |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
BR112018008864A8 (pt) | 2015-11-17 | 2019-02-26 | Pfizer | meios e métodos de fermentação para a produção de polissacarídeos em uma cultura de células bacterianas |
CN108697778B (zh) | 2016-02-16 | 2023-10-03 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
AU2018236352B2 (en) | 2017-03-15 | 2024-04-04 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
US10577665B2 (en) | 2017-09-05 | 2020-03-03 | Mcmaster University | Aptamers for clostridium difficile detection |
CN111629750B (zh) | 2017-09-28 | 2024-06-11 | 辉瑞公司 | 用于引发针对艰难梭菌的免疫应答的组合物和方法 |
JP6704173B2 (ja) | 2019-09-26 | 2020-06-03 | パナソニックIpマネジメント株式会社 | 開閉器及び分電盤 |
-
2012
- 2012-04-20 HR HRP20231631TT patent/HRP20231631T1/hr unknown
- 2012-04-20 WO PCT/IB2012/051999 patent/WO2012143902A1/en active Application Filing
- 2012-04-20 TW TW108101678A patent/TWI686402B/zh active
- 2012-04-20 IL IL270779A patent/IL270779B1/en unknown
- 2012-04-20 HU HUE19167276A patent/HUE065594T2/hu unknown
- 2012-04-20 PT PT191672765T patent/PT3549949T/pt unknown
- 2012-04-20 AU AU2012245904A patent/AU2012245904B2/en active Active
- 2012-04-20 KR KR1020137030696A patent/KR101667837B1/ko active IP Right Grant
- 2012-04-20 US US13/451,631 patent/US8481692B2/en not_active Ceased
- 2012-04-20 PL PL19167276.5T patent/PL3549949T3/pl unknown
- 2012-04-20 FI FIEP19167276.5T patent/FI3549949T3/fi active
- 2012-04-20 SG SG2013074992A patent/SG194132A1/en unknown
- 2012-04-20 SI SI201232048T patent/SI3505531T1/sl unknown
- 2012-04-20 MY MYPI2017001631A patent/MY182429A/en unknown
- 2012-04-20 EP EP12720966.6A patent/EP2699587B1/en active Active
- 2012-04-20 ES ES12720966T patent/ES2742823T3/es active Active
- 2012-04-20 JP JP2014505775A patent/JP5917682B2/ja active Active
- 2012-04-20 CN CN202010510962.7A patent/CN111647059B/zh active Active
- 2012-04-20 ES ES19151036T patent/ES2968629T3/es active Active
- 2012-04-20 SG SG10201602668VA patent/SG10201602668VA/en unknown
- 2012-04-20 RU RU2015154443A patent/RU2754446C2/ru active
- 2012-04-20 TW TW111129989A patent/TWI815599B/zh active
- 2012-04-20 EP EP19167276.5A patent/EP3549949B1/en active Active
- 2012-04-20 PT PT12720966T patent/PT2699587T/pt unknown
- 2012-04-20 PL PL19151036.1T patent/PL3505531T3/pl unknown
- 2012-04-20 BR BR112013027229-5A patent/BR112013027229B1/pt active IP Right Grant
- 2012-04-20 PE PE2013002389A patent/PE20141029A1/es active IP Right Grant
- 2012-04-20 NZ NZ616035A patent/NZ616035A/en unknown
- 2012-04-20 MX MX2013012344A patent/MX347521B/es active IP Right Grant
- 2012-04-20 TW TW106131031A patent/TWI671313B/zh active
- 2012-04-20 ES ES19167276T patent/ES2969952T3/es active Active
- 2012-04-20 SI SI201231646T patent/SI2699587T1/sl unknown
- 2012-04-20 SG SG10201911993UA patent/SG10201911993UA/en unknown
- 2012-04-20 PL PL12720966T patent/PL2699587T3/pl unknown
- 2012-04-20 TW TW109107042A patent/TWI804717B/zh active
- 2012-04-20 RU RU2013145170/10A patent/RU2592686C2/ru active
- 2012-04-20 CN CN201611125122.9A patent/CN107022532B/zh active Active
- 2012-04-20 EP EP19151036.1A patent/EP3505531B1/en active Active
- 2012-04-20 HU HUE12720966A patent/HUE047085T2/hu unknown
- 2012-04-20 TW TW101114168A patent/TWI650329B/zh active
- 2012-04-20 DK DK19167276.5T patent/DK3549949T3/da active
- 2012-04-20 BR BR122019017005-3A patent/BR122019017005B1/pt active IP Right Grant
- 2012-04-20 PE PE2018000975A patent/PE20181334A1/es unknown
- 2012-04-20 CN CN201280030656.7A patent/CN103619871B/zh active Active
- 2012-04-20 TW TW108114747A patent/TWI701257B/zh active
- 2012-04-20 DK DK12720966.6T patent/DK2699587T3/da active
- 2012-04-20 HR HRP20240042TT patent/HRP20240042T1/hr unknown
- 2012-04-20 MY MYPI2013701986A patent/MY168205A/en unknown
- 2012-04-20 AR ARP120101365A patent/AR086199A1/es active IP Right Grant
- 2012-04-20 CA CA2832712A patent/CA2832712C/en active Active
- 2012-04-20 EP EP23207942.6A patent/EP4365196A2/en active Pending
- 2012-04-20 SI SI201232051T patent/SI3549949T1/sl unknown
- 2012-04-21 SA SA115360698A patent/SA115360698B1/ar unknown
- 2012-04-21 SA SA112330472A patent/SA112330472B1/ar unknown
- 2012-04-21 SA SA115360697A patent/SA115360697B1/ar unknown
-
2013
- 2013-03-22 US US13/848,909 patent/US8557548B2/en not_active Ceased
- 2013-08-19 US US13/970,048 patent/US8900597B2/en not_active Ceased
- 2013-10-17 IL IL228944A patent/IL228944A/en active IP Right Grant
- 2013-10-21 ZA ZA2013/07818A patent/ZA201307818B/en unknown
- 2013-10-24 CO CO13252702A patent/CO6801643A2/es unknown
-
2014
- 2014-10-31 US US14/529,147 patent/US9745354B2/en active Active
-
2015
- 2015-07-10 US US14/796,741 patent/US9187536B1/en not_active Ceased
- 2015-10-14 US US14/883,000 patent/USRE46376E1/en active Active
-
2016
- 2016-01-21 JP JP2016009882A patent/JP6097853B2/ja active Active
- 2016-04-11 IL IL245047A patent/IL245047A0/en active IP Right Grant
- 2016-05-05 AU AU2016202903A patent/AU2016202903B2/en active Active
- 2016-12-01 US US15/366,702 patent/USRE46518E1/en active Active
-
2017
- 2017-02-17 JP JP2017027808A patent/JP6321239B2/ja active Active
- 2017-07-12 US US15/648,092 patent/US10774117B2/en active Active
- 2017-09-07 IL IL254440A patent/IL254440B/en active IP Right Grant
- 2017-09-11 IL IL254418A patent/IL254418B/en active IP Right Grant
- 2017-10-12 JP JP2017198569A patent/JP2018052938A/ja active Pending
- 2017-10-31 IL IL255345A patent/IL255345B/en active IP Right Grant
- 2017-11-13 AU AU2017261465A patent/AU2017261465B2/en active Active
-
2018
- 2018-02-22 AU AU2018201296A patent/AU2018201296A1/en not_active Abandoned
- 2018-04-03 JP JP2018071560A patent/JP6735784B2/ja active Active
- 2018-10-11 JP JP2018192593A patent/JP6892425B2/ja active Active
-
2019
- 2019-03-20 IL IL265510A patent/IL265510B/en active IP Right Grant
- 2019-03-20 US US16/359,267 patent/US10597428B2/en active Active
- 2019-04-18 US US16/388,011 patent/USRE48863E1/en active Active
- 2019-04-18 US US16/387,999 patent/USRE48862E1/en active Active
- 2019-10-11 AU AU2019246878A patent/AU2019246878B2/en active Active
- 2019-12-05 US US16/704,777 patent/US11535652B2/en active Active
-
2020
- 2020-03-11 IL IL273231A patent/IL273231B/en unknown
- 2020-09-08 AU AU2020230248A patent/AU2020230248B2/en active Active
-
2021
- 2021-05-27 JP JP2021088838A patent/JP7097478B2/ja active Active
-
2022
- 2022-06-27 JP JP2022102418A patent/JP2022126822A/ja active Pending
- 2022-12-15 US US18/066,591 patent/US20230391835A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2699587T3 (da) | Sammensætninger med relation til et mutant-clostridium difficile-toksin og fremgangsmåder dertil | |
IL284582A (en) | Compositions and methods related to mutant Clostridium difficile toxin | |
DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
DK3495392T3 (da) | Anti-cgrp-sammensætninger og anvendelse deraf | |
DK2763665T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
EP2744517A4 (en) | COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL ANTI-PROTEIN ANTIBODIES | |
DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
DK2661274T3 (da) | Sammensætninger og fremgangsmåder med aloepolysaccharider | |
DK2862566T3 (da) | Forbedringer i og relateret til sammensætninger | |
BR112013022530A2 (pt) | método terapêutico homeopático e composições | |
DK2633029T3 (da) | Sammensætninger og fremgangsmåder til dyrkning af spirokæter |